A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above - Regional Cancer Care Associates LLC

Clinical Trials

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Type of Cancer
Lymphoma
Locations
Bethesda
Sponsor
TG Therapeutics, Inc.
Protocol Number
TGTX-LAB-001
Cancer Diagnosis
To Learn More Call
201-510-0910